论文部分内容阅读
目的探讨马来酸罗格列酮对糖基化终产物(AGEs)诱导的人肾系膜细胞(HRMC)趋化因子RANTES高表达的影响,及其对糖尿病大鼠血清糖基化终产物-肽(AGE-P)及肾脏RANTES表达的影响。方法运用糖基化修饰的牛血清白蛋白(AGE-BSA)与马来酸罗格列酮干预体外培养的HRMC,ELISA法检测细胞培养上清中RANTES蛋白水平,实时定量RT-PCR检测细胞中RANTES mRNA水平,Western blot检测RANTES蛋白表达。制备2型糖尿病大鼠模型,马来酸罗格列酮治疗10周。流动注射分析法测定血清AGEP,免疫组织化学检测肾皮质RANTES表达。结果马来酸罗格列酮干预组HRMCRANTES的mRNA和蛋白表达以及蛋白分泌明显低于AGE-BSA组;马来酸罗格列酮治疗组糖尿病大鼠血清AGE-P明显下降,肾皮质RANTES表达明显低于糖尿病非治疗组。结论马来酸罗格列酮可以抑制AGE-BSA诱导的HRMCRANTES的表达和分泌,还可降低糖尿病大鼠血清AGE-P及肾脏RANTES表达。
Objective To investigate the effect of rosiglitazone maleate on the high expression of human renal mesangial cell (HRMC) chemokine RANTES induced by advanced glycation end products (AGEs) and its effect on the expression of serum glycosylation end products - Peptide (AGE-P) and renal RANTES expression. Methods The cultured human HRMC was treated with glycosylated bovine serum albumin (AGE-BSA) and rosiglitazone maleate in vitro. The level of RANTES protein in the cell culture supernatant was detected by ELISA. RANTES mRNA level, Western blot detection of RANTES protein expression. Rat model of type 2 diabetes mellitus was prepared and rosiglitazone maleate was given for 10 weeks. Serum AGEP was measured by flow injection analysis and RANTES expression in renal cortex was detected by immunohistochemistry. Results The mRNA and protein expression of HRMCRANTES and the protein secretion in the rosiglitazone maleate group were significantly lower than those in the AGE-BSA group. AGE-P in the serum of diabetic rats treated with rosiglitazone maleate was significantly decreased, while the expression of RANTES in renal cortex Obviously lower than non-diabetic diabetic group. Conclusion Rosiglitazone maleate can inhibit AGE-BSA-induced HRMCRANTES expression and secretion, but also reduce the serum of diabetic rats AGE-P and renal RANTES expression.